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Today, there is no SARS-CoV-2 treatment that has been proven to be effective in clinical trials. The
need to find such treatment is of utmost importance since a vaccine is not expected at least for
one year. In Table 1, the most promising candidates for the treatment of COVID-19.
There has been a great breakthrough in SARS-CoV-2 research these last few months. The best prevention to reduce the transmission of the virus for the moment is the social distancing, to control the
personal and environmental hygiene and to intensify the epidemiological surveillance networks around the world. These measures will be crucial until a treatment or vaccine was developed. However,
much research remains to be done on the SARS-CoV-2.
For the future, we should implement some measures to reduce the probability of zoonotic outbreaks:
- A greater investment in scientific research, specially in animal etiology.
- Normalize the high-risk pathogens study.
- Reduce direct contact with wildlife.
- Keep barriers among potential animals reservoirs of virus and the population.
- Outlawing the trafficking of wild animals.
We cannot discard another coronavirus outbreak in the future, so scientists suggest we should invest in the development of vaccine which confers immunity front others coronavirus.
SARS-CoV-2 (Figure 1) is an unsegmented single-stranded RNA virus. It belongs to Coronaviridae family, specifically to Betacoronavirus
genus. After SARS-CoV and MERS-CoV, SARS-CoV-2 is the third coronavirus that causes a severe disease among human population in 21st
century. The origin is unknown but genomic analyses indicate that the bat could be the natural host and the pangolin the intermediate.
SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a receptor to enter target cells, as well as SARS-CoV. To recognize the cell
receptor, the virus uses the spike (S) protein, a surface protein represented in red Figure 1.
The virus is transmitted human-to-human through droplets, aerosols, respiratory secretions and faeces. The most common symptoms include
fever, cough, fatigue, sputum production and shortness of breath. The disease can negatively evolves to pneumonia and acute respiratory
distress syndrome. The most susceptible population to the disease are the elderly and/or people with previous chronic pathologies.
Figure 1. Illustration of a
SARS-CoV-2 virion3.
Figure 2. Distribution of COVID-19 by countries on 30th May of
20201.
WHO has elaborated prevention manuals with some recommendations to slow
down disease transmission for the population1
RT-PCR Detect viral RNA from
nasopharyngeal sample
+ High specificity and sensibility
- False positives and negatives
- Slow diagnosis
- Lack of reagents
IgM and IgG 
detection
Measure the host 
immune response
+ Quick test
+ Seroprevalence
- False positives and negatives
- Less specificity than RT-PCR
THERAPEUTIC 
CANDIDATES
TARGET DISEASE TYPE OF DRUG ACTION MODE STATUS FOR 
COVID-19
Lopinavir/ritonavir
HIV, SARS, MERS Protease inhibitors Inhibiting protease for 
protein cleavage, 
resulting in non-
infectious viral particles
Clinical trials for 
COVID-19
Chloroquine/Hydro
xychloroquine
Malaria, autoimmune 
diseases
9-aminoquinolin Increasing endosomal 
pH, immunomodulating, 
autophagy inhibitors, 
interfering with the 
ACE2 glycosylation
Clinical trials for 
COVID-19
Remdesivir (GS-
5724)
Ebola Nucleotide analogue 
prodrug
Interfering with virus 
post-entry: inhibits viral 
RNA synthesis targeting 
RdRp
Phase III clinical 
trials for COVID-19
Favipiravir (T-705)
Influenza A (H1N1), 
Ebola, yellow fever, 
Chikungunya, 
norovirus and 
enterovirus
Guanine analogue Interfering with virus 
post-entry: inhibits viral 
RNA synthesis targeting 
RdRp
Clinical trials for 
COVID-19
Tocilizumab
Cytokine release 
syndrome, 
rheumatoid arthritis
Recombinant 
humanized 
monoclonal antibody
IL-6 receptor antagonist: 
blocks the cytokine 
storm release 
Clinical trials for 
COVID-19
Figure 3. Most advanced candidate vaccines in research.
Figures elaborated with Biorender.
Table 1. List of therapeutic candidates for COVID-19 treatment and their features.
On December 2019, several cases of pneumonia caused by a novel β-coronavirus identified were reported in Wuhan, China. The virus was 
named SARS-CoV-2 and the related disease COVID-19. On 25th May of 2020, the COVID-19 had affected more than 200 countries and 
territories, with  5.267.419 infections and 341.155 deceased1. 
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